Cognition Therapeutics Advances Zervimesine in Clinical Trials

Introduction

Cognition Therapeutics Inc (NASDAQ: CGTX), also known in Korean as 커그니션 테라퓨틱스, is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neurodegenerative disorders. As of July 10, 2025, CGTX shares closed at $0.9329, reflecting a 75.26% gain on a trading volume of 55,431,230 shares on the Nasdaq exchange.

Corporate Structure and Leadership

Founded in 2007 and headquartered in Purchase, New York, Cognition Therapeutics employs 11–50 people dedicated to neuroscience research, drug development, and clinical trials. The company’s senior management team combines industry and academic expertise:

Lisa Ricciardi serves as Chief Executive Officer and President. Since March 2020, she has overseen corporate strategy and capital raises. Her previous roles include CEO of Suono Bio and senior business development positions at Pfizer, Foundation Medicine, and Express Scripts.

Anthony O. Caggiano, M.D., Ph.D., is Chief Medical Officer and Head of R&D. With 17 years at Acorda Therapeutics directing neurology programs, he leads clinical development for the company’s pipeline.

John Doyle joined as Chief Financial Officer in 2023, bringing experience from 4D Pharma plc and Chiasma Inc. He manages financing strategies amid evolving market conditions.

Anita Cornet, Head of Quality since 2024, ensures that manufacturing and technical operations meet U.S. FDA and global standards. Her background includes roles at Acorda Therapeutics and GlaxoWellcome.

Neurodegenerative Disorders by Milad Fakurian

Developments and News

On December 18, 2024, Cognition reported topline results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB). The trial enrolled 130 patients over six months, reporting improvements across behavioral, functional, cognitive, and movement measures, including an 82% slowing in neuropsychiatric inventory decline. Detailed data were presented at the International Lewy Body Dementia Conference in January 2025.

On June 21, 2025, the company announced an anonymous philanthropic donation to fund an expanded access program (EAP) for zervimesine in DLB. The Banner Sun Health Research Institute, led by Dr. David Shprecher, is the first activated site.

According to a June 2025 update on LinkedIn, the Phase 2 START study in mild cognitive impairment and early Alzheimer’s disease surpassed 50% enrollment. This trial will randomize up to 540 participants to receive once-daily oral zervimesine or placebo over 18 months.

In filings with the U.S. Securities and Exchange Commission in early June 2025 (Forms 8-K dated June 2 and June 3), Cognition reported updates under items 8.01 and 9.01, although detailed financial metrics were not disclosed. A June 20, 2025 Form 8-K (item 5.07) noted a change in fiscal year end.

Financial and Strategic Analysis

Cognition Therapeutics remains a clinical-stage company and relies on equity financings and philanthropic support to fund research and development. The significant share price increase on July 10, 2025, and elevated trading volume indicate market interest possibly related to recent clinical data and expanded access program announcements.

Strategically, the company is advancing zervimesine through multiple clinical programs: SHIMMER in DLB, START in Alzheimer’s disease, and a completed study in dry age-related macular degeneration. Plans to engage the U.S. Food and Drug Administration in an end-of-Phase 2 meeting suggest a pathway toward late-stage trials. Expanded access initiatives aim to provide patient data supportive of regulatory submissions and real-world safety.

Market Position and Industry Context

Cognition operates in the neurosciences segment of biotechnology, targeting sigma-2 receptors to antagonize toxic oligomer accumulation in neurons. Alzheimer’s disease and DLB together represent a multibillion-dollar market with limited disease-modifying treatments. Zervimesine’s oral, once-daily profile differentiates it from monoclonal antibodies and injectables under development by larger companies. Successful late-stage trials could position CGTX among a small group of companies offering first-in-class therapies for neurodegeneration.

tl;dr

Cognition Therapeutics (NASDAQ: CGTX) reported Phase 2 SHIMMER results on December 18, 2024, indicating clinical benefits of zervimesine in dementia with Lewy bodies, and launched an expanded access program funded by a philanthropic gift on June 21, 2025. The Phase 2 START Alzheimer’s study achieved over 50% enrollment as of June 2025. A forthcoming FDA end-of-Phase 2 meeting and ongoing SEC filings are indicative of late-stage trial planning; shares closed at $0.9329 (+75.26%) on July 10, 2025.